全文获取类型
收费全文 | 7853篇 |
免费 | 553篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 228篇 |
妇产科学 | 196篇 |
基础医学 | 1243篇 |
口腔科学 | 184篇 |
临床医学 | 543篇 |
内科学 | 1912篇 |
皮肤病学 | 323篇 |
神经病学 | 805篇 |
特种医学 | 117篇 |
外科学 | 805篇 |
综合类 | 39篇 |
预防医学 | 649篇 |
眼科学 | 179篇 |
药学 | 619篇 |
中国医学 | 34篇 |
肿瘤学 | 508篇 |
出版年
2023年 | 62篇 |
2022年 | 126篇 |
2021年 | 253篇 |
2020年 | 158篇 |
2019年 | 270篇 |
2018年 | 281篇 |
2017年 | 194篇 |
2016年 | 218篇 |
2015年 | 245篇 |
2014年 | 335篇 |
2013年 | 376篇 |
2012年 | 599篇 |
2011年 | 612篇 |
2010年 | 347篇 |
2009年 | 300篇 |
2008年 | 499篇 |
2007年 | 431篇 |
2006年 | 441篇 |
2005年 | 434篇 |
2004年 | 409篇 |
2003年 | 361篇 |
2002年 | 369篇 |
2001年 | 110篇 |
2000年 | 114篇 |
1999年 | 116篇 |
1998年 | 81篇 |
1997年 | 56篇 |
1996年 | 53篇 |
1995年 | 39篇 |
1994年 | 37篇 |
1993年 | 23篇 |
1992年 | 45篇 |
1991年 | 46篇 |
1990年 | 55篇 |
1989年 | 36篇 |
1988年 | 34篇 |
1987年 | 34篇 |
1986年 | 23篇 |
1985年 | 29篇 |
1984年 | 13篇 |
1983年 | 20篇 |
1981年 | 10篇 |
1979年 | 10篇 |
1978年 | 9篇 |
1975年 | 9篇 |
1974年 | 9篇 |
1973年 | 9篇 |
1972年 | 14篇 |
1971年 | 11篇 |
1966年 | 9篇 |
排序方式: 共有8436条查询结果,搜索用时 15 毫秒
81.
Iranzu González Enrique J Andreu Angel Panizo Susana Inogés Ana Fontalba José Luis Fernández-Luna Mirella Gaboli Luis Sierrasesúmaga Salvador Martín-Algarra Javier Pardo Felipe Prósper Enrique de Alava 《Clinical cancer research》2004,10(2):751-761
PURPOSE AND EXPERIMENTAL DESIGN: The stem cell factor/KIT receptor loop may represent a novel target for molecular-based therapies of Ewing tumor. We analyzed the in vitro impact of KIT blockade by imatinib in Ewing tumor cell lines. RESULTS: KIT expression was detected in 4 of 4 Ewing tumor cell lines and in 49 of 110 patient samples (44.5%) by immunohistochemistry and/or Western blot analysis. KIT expression was stronger in Ewing tumors showing EWS-FLI1 nontype 1 fusions. Despite absence of c-kit mutations, constitutive and ligand-inducible phosphorylation of KIT was found in all tumor cell lines, indicating an active receptor. Treatment with KIT tyrosine kinase inhibitor imatinib (0.5-20 micro M) induced down-regulation of KIT phosphorylation and dose response inhibition of cell proliferation (IC(50), 12-15 micro M). However, imatinib administered alone at doses close to IC(50) for growth inhibition (10 micro M) did not induce a significant increase in apoptosis. We then analyzed if blockade of KIT loop through imatinib (10 micro M) was able to increase the antitumor in vitro effect of doxorubicin (DXR) and vincristine (VCR), drugs usually used in Ewing tumor treatment. Addition of imatinib decreased in 15-20 and 15-36% of the proliferative rate of Ewing tumor cells exposed to DXR and VCR, respectively, and increased in 15 and 30% of the apoptotic rate of Ewing tumor cells exposed to the same drugs. CONCLUSIONS: Inhibition of Ewing tumor cell proliferation by imatinib is mediated through blockade of KIT receptor signaling. Inhibition of KIT increases sensitivity of these cells to DXR and VCR. This study supports a potential role for imatinib in the treatment of Ewing tumor. 相似文献
82.
Lilia Suárez María-Belén Vidriales José García-Lara?a Guillermo Sanz María-José Moreno Antonio López Susana Barrena Rafael Martínez Mar Tormo Luis Palomera Esperanza Lavilla Ma Consuelo López-Berges María de Santiago M Encarnación Pérez de Equiza Jesús F San Miguel Alberto Orfao 《Clinical cancer research》2004,10(22):7599-7606
Myelodysplastic syndromes and acute myeloid leukemia (AML) are heterogeneous disorders in which conflicting results in apoptosis and multidrug resistance (MDR) have been reported. We have evaluated by multiparameter flow cytometry the expression of apoptosis- (APO2.7, bcl-2, and bax) and MDR-related proteins [P-glycoprotein (P-gp), multidrug resistance protein (MRP), and lung resistance protein (LRP)] specifically on bone marrow (BM) CD34+ cells, and their major CD32-/dim and CD32+ subsets, in de novo AML (n=90), high-risk myelodysplastic syndrome (n=9), and low-risk myelodysplastic syndrome (n=21) patients at diagnosis, and compared with normal BM CD34+ cells (n=6). CD34+ myeloid cells from AML and high-risk myelodysplastic syndrome patients displayed higher expression of bcl-2 (P <0.0001) and lower reactivity for APO2.7 (P=0.002) compared with low-risk myelodysplastic syndrome and normal controls. Similar results applied to the two predefined CD34+ myeloid cell subsets. No significant differences were found in the expression of P-gp, MRP, and LRP between low-risk myelodysplastic syndrome patients and normal BM, but decreased expression of MRP (P <0.03) in AML and high-risk myelodysplastic syndromes and P-gp (P=0.008) in high-risk myelodysplastic syndromes were detected. Hierarchical clustering analysis showed that low-risk myelodysplastic syndrome patients were clustered next to normal BM samples, whereas high-risk myelodysplastic syndromes were clustered together and mixed with the de novo AML patients. In summary, increased resistance to chemotherapy of CD34+ cells from both AML and high-risk myelodysplastic syndromes would be explained more appropriately in terms of an increased antiapoptotic phenotype rather than a MDR phenotype. In low-risk myelodysplastic syndromes abnormally high apoptotic rates would be restricted to the CD34- cell compartments. 相似文献
83.
84.
Fernando Arias de la Vega Miguel Angel Domínguez Domínguez Ana Manterola Burgaleta Ruth Vera García Maria Eugenia Echeverría Zabalza Eugenio Oria Mundin Enrique Martínez López Pilar Romero Rojano Elena Villafranca Iture 《Clinical & translational oncology》2005,7(2):60-65
INTRODUCTION: This study aims to asses the effectiveness and toxicity of boost radiotherapy concomitant and concurrent cisplatin for patients with locally advanced head and neck cancer (LAHNC). MATERIAL AND METHODS: There were 30 patients included in a prospective, phase II single-institution trial and of whom, 29 were at AJCC stage IV and 1 at stage III. Treatment consisted of radiotherapy acceleration fractionation with concomitant boost, 72 Gy, and 2 cycles of concomitant cisplatin (20 mg/m2/day continuous infusion; days 1-5 and 29-33). Amifostine, (i.v. 200 mg/m2) was administered to 26 prior to the first fraction of radiotherapy. Endpoints of the study were quality-of-life (QL), overall survival, and local control of disease. RESULTS: Complete response (CR) was achieved in 23 patients (77%), 2 patients had partial response (PR) (7%), 4 had no response (13%), and 1 was not evaluated for response. The 2-year overall survival and loco-regional control were 60% and 56%, respectively. Main toxicity was grade 3 or 4 mucositis in 93% of the patients. QL scores (questionnaire QLQC30; version 3.0) and the HN cancer module QLQ-HN35) showed a worsening in areas related to the treatment e.g. dry mouth, problems stretching the mouth, and sticky saliva. CONCLUSIONS: this combination modality is active, but toxic, in the treatment for LAHNC. Concomitant boost radiotherapy is probably, not the best radiotherapy schema for combining with chemotherapy in LAHNC. 相似文献
85.
Susana B Bravo María E R García-Rendueles Rafael Seoane Vanesa Dosil José Cameselle-Teijeiro Luis López-Lázaro Juan Zalvide Francisco Barreiro Celia M Pombo Clara V Alvarez 《Clinical cancer research》2005,11(21):7664-7673
Undifferentiated (anaplastic) thyroid carcinoma is a highly aggressive human cancer with very poor prognosis. Although there have been a few studies of candidate treatments, the fact that it is an infrequent tumor makes it very difficult to design clinical trials. A strong association has been observed between undifferentiated thyroid carcinoma and TP53 mutations in numerous molecular genetic and expression studies. Plitidepsin (Aplidin, PharmaMar, Madrid, Spain) is a novel anticancer compound obtained from a sea tunicate. This compound has been reported to induce apoptosis independently of TP53 status. We investigated the actions of plitidepsin in human thyroid cancer cells. In initial experiments using primary cultured cells from a differentiated (papillary) carcinoma, we found that 100 nmol/L plitidepsin induced apoptosis, whereas lower doses were cytostatic. Because our aim was to study the effects of plitidepsin at clinically relevant concentrations, subsequent experiments were done with a dosage regimen reflecting plasma concentrations observed in previously reported clinical trials: 100 nmol/L for 4 hours, followed by 10 nmol/L for 20 hours (4(100)/20(10) plitidepsin). This plitidepsin dosage regimen blocked the proliferation of a primary undifferentiated/anaplastic thyroid carcinoma culture obtained in our laboratory and of a commercial cell line (8305C) obtained from an undifferentiated thyroid carcinoma; however, it did not induce apoptosis. The proportion of cells in the G(1) phase of the cell cycle was greatly increased and the proportion in the S/G(2)-M phases greatly reduced, suggesting that plitidepsin blocks G(1)-to-S transition. Levels of the cyclin D1/cyclin-dependent kinase 4/p21 complex proteins were decreased and, in line with this, the levels of unphosphorylated Rb1 increased. The decrease in cell cycle proteins correlated with hypoacetylation of histone H3. Finally, we did experiments to assess how rapidly tumor cells return to their initial pretreatment proliferative behavior after 4(100)/20(10) plitidepsin treatment. Cells from undifferentiated tumors needed more than 3 days to recover logarithmic growth, and after 7 days, cell number was still significantly lower than in control cultures. 4(100)/20(10) plitidepsin inhibited the growth in soft agar. Together, our data show that plitidepsin is able to block in vitro cell cycle progression at concentrations similar to serum concentrations observed in vivo, and that this effect is persistent for several days after plitidepsin removal. Whether plitidepsin will prove to be clinically useful in the treatment of undifferentiated thyroid cancers remains to be established. However, our results raise the possibility that plitidepsin might be effective alone or in combination with radiotherapy and/or other drug treatments. 相似文献
86.
Amparo Rodríguez Sánchez María J. Chueca Guindulain María Alija Merillas Susana Ares Segura José Carlos Moreno Navarro María Dolores Rodríguez Arnao 《Anales de pediatría (Barcelona, Spain : 2003)》2019,90(4):250.e1-250.e8
The screening program of congenital hypothyroidism (CH) is probably one of the best achievements in paediatrics. Thyroid hormones are essential for brain development and brain maturation that continue through the neonatal period. Hypothyroidism that begins in the first months of life causes irreversible damage to the central nervous system, and is one of the most frequent and preventable causes of mental retardation. As children with congenital hypothyroidism are born with a normal appearance, analytical studies are required to immediately start the appropriate therapy.This article analyses the aims, diagnostic procedures, tests required, aetiology, and differential diagnosis in this disorder. Especially relevant is to perform frequent monitoring to ensure dose adjustments of L-Thyroxine therapy, avoiding infra- or supra-dosing that negatively affects neurosensory functions. Re-evaluation of the aetiology permanent vs transient hypothyroidism is always recommended after 3 years of chronological age.The relevance of this screening program should be widely discussed in paediatrics. The main objective is to avoid cerebral damage in these patients, and has been highly successful and economically beneficial.Other aspects are required to optimise patient outcomes, to perform all the controls according to the recommendations and to include, in the near future, the diagnosis of central hypothyroidism. Implementation of this program is necessary to progress in accordance with current scientific knowledge. 相似文献
87.
Simone Ribero John R. Davies Celia Requena Cristina Carrera Daniel Glass Ramon Rull Sergi Vidal‐Sicart Antonio Vilalta Lucia Alos Virtudes Soriano Pietro Quaglino Victor Traves Julia A. Newton‐Bishop Eduardo Nagore Josep Malvehy Susana Puig Veronique Bataille 《International journal of cancer. Journal international du cancer》2015,137(7):1691-1698
A high number of nevi is the most significant phenotypic risk factor for melanoma and is in part genetically determined. The number of nevi decreases from middle age onward but this senescence can be delayed in patients with melanoma. We investigated the effects of nevus number count on sentinel node status and melanoma survival in a large cohort of melanoma cases. Out of 2,184 melanoma cases, 684 (31.3%) had a high nevus count (>50). High nevus counts were associated with favorable prognostic factors such as lower Breslow thickness, less ulceration and lower mitotic rate, despite adjustment for age. Nevus count was not predictive of sentinel node status. The crude 5‐ and 10‐year melanoma‐specific survival rate was higher in melanomas cases with a high nevus count compared to those with a low nevus count (91.2 vs. 86.4% and 87.2 vs. 79%, respectively). The difference in survival remained significant after adjusting for all known melanoma prognostic factors (hazard ratio [HR] = 0.43, confidence interval [CI] = 0.21–0.89). The favorable prognostic value of a high nevus count was also seen within the positive sentinel node subgroup of patients (HR = 0.22, CI = 0.08–0.60). High nevus count is associated with a better melanoma survival, even in the subgroup of patients with positive sentinel lymph node. This suggests a different biological behavior of melanoma tumors in patients with an excess of nevi. 相似文献
88.
Víctor Moreno-Torres Carmen de Mendoza Susana Mellor-Pita María Martínez-Urbistondo Pedro Durn-del Campo Pablo Tutor-Ureta Jos-Manuel Vzquez-Comendador Jorge Caldern-Parra Elena Múez-Rubio Antonio Ramos-Martínez Ana Fernndez-Cruz Raquel Castejn Juan-Antonio Vargas-Nuez 《Viruses》2022,14(8)
We aimed to evaluate the clinical outcome of Systemic Autoimmune Diseases (SADs) patients hospitalized with COVID-19 in Spain, before the introduction of SARS-CoV-2 vaccines. A nationwide, retrospective and observational analysis of the patients admitted during 2020, based on the ICD10 codes in the National Registry of Hospital Discharges, was performed. Among 117,694 patients, only 892 (0.8%) presented any type of SAD before COVID-19-related admission: Sjogren’s Syndrome constituted 25%, Systemic Vasculitides 21%, Systemic Lupus Erythematosus 19%, Sarcoidosis 17%, Systemic Sclerosis 11%, Mixed and Undifferentiated Connective Tissue Disease 4%, Behçet’s Disease 4% and Inflammatory Myopathies 2%. The in-hospital mortality rate was higher in SAD individuals (20% vs. 16%, p < 0.001). After adjustment by baseline conditions, SADs were not associated with a higher mortality risk (OR = 0.93, 95% CI 0.78–1.11). Mortality in the SADs patients was determined by age (OR = 1.05, 95% CI 1.04–1.07), heart failure (OR = 1.67, 95% CI 1.10–2.49), chronic kidney disease (OR = 1.29, 95% CI 1.05–1.59) and liver disease (OR = 1.97, 95% CI 1.13–3.44). In conclusion, the higher COVID-19 mortality rate seen in SADs patients hospitalized in Spain in 2020 was related to the higher burden of comorbidities, secondary to direct organ damage and sequelae of their condition. Whilst further studies should evaluate the impact of baseline immunosuppression on COVID-19 outcomes in this population, efforts should be focused on the optimal management of SAD to minimize the impact of the organ damage that has been shown to determine COVID-19 prognosis. 相似文献
89.
90.
Kevin Soler-Carracedo María Díaz-Gonzlez Inocencio R. Martin Susana Rios Beatriz Gil-Hernndez Gabriela Brito-Santos Joaquín Sanchiz 《Materials》2022,15(21)
A new Eu3+-doped Gd3+ complex of formula [Eu0.0135Gd0.9865(pta)3me-phen] was synthesized and structurally characterized (Hpta = benzoyltrifluoroacetone, me-phen = 5-methyl-1,10-phenanthroline). The photoluminescence study revealed that when the compound was excited at RT, under a 457 nm continuous laser, the material exhibited high luminescence due to the antenna effect of the ligands, as well as a good balance between the phosphorescence from the spin-forbidden triplet (from the organic ligands), and the characteristic lanthanide f-f transitions. The ratio between the previous emissions drastically changed when the sample was heated up to 62 °C inside a tubular furnace. This ratio was investigated using the luminescence intensity ratio method, to analyze the capabilities of the sample as a temperature sensor. The relative sensitivity reached a maximum of 11.4 °C−1 %, maintaining a detection limit below 0.15 °C for the whole temperature range. 相似文献